Article Per Year (5 Year)
p-Index From 2020 - 2025
1.037
P-Index
This Author published in this journals
All Journal International Journal of Integrated Health Sciences Indonesian Journal of Cardiology
Pramudyo, Miftah
Unknown Affiliation
Health Professions Medicine & Pharmacology

Published : 5 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 5 Documents
Search

 1 
Correlation between MMP-9 Level and Diastolic Dysfunction in Concentric Left Ventricular Hypertrophy Patients Pramudyo, Miftah; Jungjunan, Ridho; Martanto, Erwan; Achmad, Chaerul
International Journal of Integrated Health Sciences Vol 9, No 1 (2021)
Publisher : Faculty of Medicine Universitas Padjadjaran

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.15850/ijihs.v9n1.2175

Abstract

Objective: To establish the relationship between plasma matrix metalloproteinase (MMP)-9 levels and diastolic functional abnormalities using the E/e’ measurement in concentric type Hypertensive Heart Disease (HHD) patients.Methods: A cross-sectional study was conducted from November 2014 to January 2015 in population with hypertension and concentric Left Ventricular Hypertrophy (LVH). Diastolic function was assessed with E/e’ measurement using echocardiography. The relationship between the two variables was analyzed using Spearman correlation.Results: Thirty-nine subjects (14 males, 35.9%) with the average relative wall thickness of 0.7(±0.15), average body weight of 63.45 (±12.97) kg, average height of 155.51 (±7.12) cm, average body mass index of 26.23 (±5.08) kg/m2, and mean age of 55 (±10) years were fit to be included in the analysis. The median systolic blood pressure was 140 (110-220) mmHg while the median diastolic blood pressure and median left ventricular mass index were 80 (70-110) mmHg and 119.24 (103.05-205.69) g/m2, respectively. The median MMP-9 was measured at 108 (4-460) ng/mL and the median E/e' was 10.99 (6.2-20.42). There was a significant positive correlation between MMP-9 and E/e' (r = 0.416, p = 0.004).Conclusion: There is a significant moderate positive correlation between the MMP-9 level and diastolic dysfunction in concentric LVH patients. 
Usefulness of The CHADS2 and CHA2DS2-VASc Scores in Predicting In-Hospital Mortality in Acute Coronary Syndrome Patients: A Single-Center Retrospective Cohort Study Pramudyo, Miftah; Putra, Iwan Cahyo Santosa; Pratama, Fahmi Bagus; Pranata, Raymond
Jurnal Kardiologi Indonesia Vol 44 No 1 (2023): Indonesian Journal of Cardiology: January - March 2023
Publisher : The Indonesian Heart Association

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.30701/ijc.1294

Abstract

Background Although the GRACE risk score is widely accepted as an established scoring system to predict in-hospital mortality in acute coronary syndrome (ACS) patients, this scoring system still depends on electrocardiography and laboratory findings to determine the results. Therefore, we aim to retrospectively evaluate the association between the CHADS2 and CHA2DS2-VASc score as an anamnesis-only mediated scoring system and in-hospital mortality in hospitalized ACS patients. Methods This retrospective cohort study analyzed data of ACS patients from the ACS registry in Dr. Hasan Sadikin Central General Hospital from 2018 to 2021. The outcome of this study was in-hospital mortality. The association between these scoring system and in-hospital mortality were evaluated using binary logistic regression analysis. Receiver operating characteristics (ROC) analysis was also performed to assess the success rate of this scoring system in predicting in-hospital mortality. Results A total of 1339 patients were included in this study, and 162 (12.1%) of them died in the hospital. High CHA2DS2-VASc score group (cut-off >2) was significantly associated with higher risk of in-hospital mortality before (OR=2.56 [1.75,3.75]; p<0.001) and after adjustment of several confounding factors (OR=3.39 [1.73,6.64]; p<0.001). Meanwhile, the high CHADS2 score (cutoff >2) was only significantly increased the risk of in-hospital mortality in univariate analysis (OR=2.05[1.47,2.87];p<0.001), but was not significantly associated with in-hospital mortality after multivariate analysis (OR=1.31 [0.92,1.86];p=0.129). ROC analysis revealed that predictive accuracy of CHA2DS2-VASc score was significantly greater compared to CHADS2 score (AUC: 0.653 vs 0.609, p<0.001). However, the predictive value of CHA2DS2-VASc score was significantly lower than the GRACE risk score (AUC: 0.789 vs 0.653, p<0.001). Conclusion Our study showed that the CHA2DS2-VASc score >2 was significantly and independently associated with higher in-hospital mortality in ACS patients compared to the CHA2DS2-VASc score of 1 or lower. Despite its lower predictive accuracy compared to the GRACE risk score, CHA2DS2-VASc score can still be used in practical situations as an alternative scoring system in predicting in-hospital mortality in ACS patients, especially in primary health care settings located in rural areas that lack the diagnostic facilities.
Management of Decongestion in Acute Heart Failure: Time for a New Approach? Pramudyo, Miftah
Jurnal Kardiologi Indonesia Vol 43 No 2 (2022): Indonesian Journal of Cardiology: April - June 2022
Publisher : The Indonesian Heart Association

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.30701/ijc.1381

Abstract

As the primary cause of hospitalization in acute heart failure (AHF) patients, congestion was responsible for a higher risk of mortality, rehospitalization, and renal dysfunction in AHF patients. Although loop diuretic was routinely used as the mainstay of AHF therapy, it is still ineffective to obtain the euvolemic state in most hospitalized AHF patients. Therefore, a higher loop diuretic dose was often required to increase the decongestion effect. However, consequently, it can cause several detrimental complications, including renal dysfunction, neurohormonal activation, hyponatremia, hypokalaemia, and reduced blood pressure, which eventually result in poor prognosis. Hence, the new approach may be proposed to optimize decongestion in acute phase, including the use of arginine vasopressin V2 receptor antagonist – Tolvaptan. As an additive therapy to loop diuretic in AHF patients, it can be considered due to its several beneficial effects, including greater decongestion effect, lowered worsening renal function incidence, counteract neurohormonal activation, neutralized hyponatraemic state, no alteration of potassium metabolism, stabilize the blood pressure, and reduced requirement of a higher dose of loop diuretic to achieve an equal or even greater decongestion effect compared to a high dose of loop diuretic alone. Tolvaptan provided favourable outcomes in several specific populations and was considered safe with several mild adverse effects. Several guidelines across countries have approved the use of Tolvaptan in AHF patients with or without hyponatremia. The initial dose of Tolvaptan was 7.5 to 15 mg and can be titrated up to 30 mg. However, further studies were still required to determine the timing dose and optimal dose of Tolvaptan in general and elderly populations with AHF, respectively.
Management of Acute Coronary Syndrome Indonesia : Insight from One ACS Multicenter Registry Juzar, Dafsah Arifa; Muzakkir, Akhtar Fajar; Ilhami, Yose Ramda; Taufiq, Nahar; Astiawati, Tri; R A, I Made Junior; Pramudyo, Miftah; Priyana, Andria; Hakim, Afdhalun; Anjarwani, Setyasih; Endang, Jusup; Widyantoro, Bambang
Jurnal Kardiologi Indonesia Vol 43 No 2 (2022): Indonesian Journal of Cardiology: April - June 2022
Publisher : The Indonesian Heart Association

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.30701/ijc.1406

Abstract

Background Acute coronary syndrome (ACS) is a life-threatening disorder which contributes to high morbidity and mortality in the world. Registry of ACS offers a great guidance for improvement and research. We collated a multicentre registry to gain information about demographic, management, and outcomes of ACS in Indonesia. Methods IndONEsia Acute Coronary Syndrome Registry (One ACS Registry) was a prospective nationwide multicenter registry with 14 hospitals participating in submitting data of ACS via standardized electronic case report form (eCRF). Between July 2018 and June 2019, 7634 patients with ACS were registered. This registry recorded baseline characteristics; onset, awareness, and transfer time; physical examination and additional test; diagnosis; in-hospital medications and intervention; complications; and in-hospital outcomes. Results Nearly half of patients (48.8%) were diagnosed with STE-ACS. Most prevalent risk factors were male gender, smoking, hypertension. Patients with NSTE-ACS tended to have more concomitant diseases including diabetes mellitus, dyslipidemia, prior AMI, HF, PCI, and CABG. Majority of ACS patients in our registry (89.4%) were funded by national health coverage. Antiplatelet, anticoagulant, antihypertensive, and statins were prescribed as 24-hours therapy and discharge therapy; however presription of potent P2Y12 inhibitor was low. More STE-ACS patients underwent reperfusion therapy than non-reperfusion (65.2% vs. 34.8%), and primary PCI was the most common method (45.7%). Only 21.8% STE-ACS patients underwent reperfusion strategy within 0-3 hours of onset. Invasive strategy performed in 17.6% of NSTE-ACS patients, and only 6.7% performed early (within <24 hours). Patients underwent early invasive strategy had a shorter median LoS than late invasive strategy (P<0.001). A shorter median LoS also found in intermediate and low risk patients. Mortality rate in our ACS patients was 8.9%; STE-ACS patients showed higher mortality than NSTE-ACS (11.7 vs. 6.2%). Conclusion Our registry showed a comparable proportion between STE- and NSTE-ACS patients, with male gender predominant in middle age. Both STE- and NSTE-ACS sharing the same risk factors. We need an improvement in referral time, especially in patients with STE-ACS. Evidence from our registry showed that there are two issues that need to be addressed in order to improve ACS outcomes: optimal and adequate medical treatment and invasive strategy.
Mexiletine in the treatment of LQT2, LQT3, and acquired LQTS: a meta-analysis Ihsan, Dhiya; Iqbal, Mohammad; Cool, Charlotte Johanna; Achmad, Chaerul; Pramudyo, Miftah; Prameswari, Hawani Sasmaya; Akbar, Mohammad Rizki
Jurnal Kardiologi Indonesia Vol 46 No 2 (2025): April - June, 2025
Publisher : The Indonesian Heart Association

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.30701/ijc.1835

Abstract

Background: High mortality in patients with Long QT Syndrome (LQTS) can be reduced with proper treatment. Gene-specific therapy is crucial, as many treatments are not equally effective across different LQTS types. While mexiletine has been established in the treatment of LQT3, its use in other types of LQT need further evaluation. Methods: A meta-analysis was conducted using systematic electronic searches of PubMed, Embase, and Cochrane Library. We assessed QTc reduction and cardiac events after Mexiletine treatment. Inclusion criteria: any study with no language restriction that diagnoses any type of LQTS, uses mexiletine treatment, and provides QTc comparison before and after treatment. Animal studies were excluded. The NIH Study Quality Assessment Tools and Newcastle-Ottawa Scale were used to evaluate bias. Data were analyzed using Review Manager 5.4 and MedCalc software Results: Nine studies (n=281) were included. Mexiletine reduced QTc by -64ms (mean difference [MD], -64.22; 95% confidence interval [CI] -76.13 to -52.30; p<.001; I2 60%). Sensitivity and subanalyses showed consistent efficacy. In five studies (n=76), the number of patient with high-risk QTc (>500ms) significantly decreased (Risk Ratio [RR], 0.38; 95% CI 0.26-0.55; p<.001). Five studies (n=141) showed a significant reduction in cardiac events (RR, 0.25; 95% CI 0.14-0.44; p<.001). Two studies reported gastrointestinal (GI) problems and vertigo as side effects of mexiletine treatment. Conclusion: Mexiletine significantly reduces QTc and cardiac events in LQT2, LQT3, and aLQT patients. Mexiletine also significantly reduces the number of Long QT patients with high-risk QTc Funding: No external funding was received for this study Registration: CRD420250652574
Co-Authors Akbar, Mohammad Rizki Andria Priyana Anjarwani, Setyasih Astiawati, Tri Bambang Widyantoro Chaerul Achmad Cool, Charlotte Johanna Endang, Jusup Erwan Martanto Hakim, Afdhalun Ihsan, Dhiya Ilhami, Yose Ramda Jungjunan, Ridho Juzar, Dafsah Arifa Muzakkir, Akhtar Fajar Nahar Taufiq, Nahar Prameswari, Hawani Sasmaya Pranata, Raymond Pratama, Fahmi Bagus Putra, Iwan Cahyo Santosa R A, I Made Junior